These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 35739301)

  • 1. Repositioning canakinumab for non-small cell lung cancer-important lessons for drug repurposing in oncology.
    Lythgoe MP; Prasad V
    Br J Cancer; 2022 Sep; 127(5):785-787. PubMed ID: 35739301
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Canakinumab with and without pembrolizumab in patients with resectable non-small-cell lung cancer: CANOPY-N study design.
    Garrido P; Pujol JL; Kim ES; Lee JM; Tsuboi M; Gómez-Rueda A; Benito A; Moreno N; Gorospe L; Dong T; Blin C; Rodrik-Outmezguine V; Passos VQ; Mok TS
    Future Oncol; 2021 Apr; 17(12):1459-1472. PubMed ID: 33648347
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overcoming immunosuppression and pro-tumor inflammation in lung cancer with combined IL-1β and PD-1 inhibition.
    Lee JM; Tsuboi M; Kim ES; Mok TS; Garrido P
    Future Oncol; 2022 Sep; 18(27):3085-3100. PubMed ID: 36004638
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial.
    Ridker PM; MacFadyen JG; Thuren T; Everett BM; Libby P; Glynn RJ;
    Lancet; 2017 Oct; 390(10105):1833-1842. PubMed ID: 28855077
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A review of canakinumab and its therapeutic potential for non-small cell lung cancer.
    Schenk KM; Reuss JE; Choquette K; Spira AI
    Anticancer Drugs; 2019 Oct; 30(9):879-885. PubMed ID: 31503012
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial.
    Ridker PM; MacFadyen JG; Everett BM; Libby P; Thuren T; Glynn RJ;
    Lancet; 2018 Jan; 391(10118):319-328. PubMed ID: 29146124
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Residual inflammatory risk associated with interleukin-18 and interleukin-6 after successful interleukin-1β inhibition with canakinumab: further rationale for the development of targeted anti-cytokine therapies for the treatment of atherothrombosis.
    Ridker PM; MacFadyen JG; Thuren T; Libby P
    Eur Heart J; 2020 Jun; 41(23):2153-2163. PubMed ID: 31504417
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS).
    Ridker PM; Libby P; MacFadyen JG; Thuren T; Ballantyne C; Fonseca F; Koenig W; Shimokawa H; Everett BM; Glynn RJ
    Eur Heart J; 2018 Oct; 39(38):3499-3507. PubMed ID: 30165610
    [TBL] [Abstract][Full Text] [Related]  

  • 10. First Anti-PD-L1 Drug Approved for NSCLC.
    Cancer Discov; 2016 Dec; 6(12):OF1. PubMed ID: 27920140
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of Canakinumab for Prevention of Recurrent Cardiovascular Events.
    Sehested TSG; Bjerre J; Ku S; Chang A; Jahansouz A; Owens DK; Hlatky MA; Goldhaber-Fiebert JD
    JAMA Cardiol; 2019 Feb; 4(2):128-135. PubMed ID: 30649147
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of IL1β by Canakinumab May Be Effective against Diverse Molecular Subtypes of Lung Cancer: An Exploratory Analysis of the CANTOS Trial.
    Wong CC; Baum J; Silvestro A; Beste MT; Bharani-Dharan B; Xu S; Wang YA; Wang X; Prescott MF; Krajkovich L; Dugan M; Ridker PM; Martin AM; Svensson EC
    Cancer Res; 2020 Dec; 80(24):5597-5605. PubMed ID: 33023946
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotherapy for non-small cell lung cancer.
    Vafadar S
    JAAPA; 2019 Sep; 32(9):37-42. PubMed ID: 31460972
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Canakinumab for secondary prevention of atherosclerotic disease.
    Capodanno D; Angiolillo DJ
    Expert Opin Biol Ther; 2018 Feb; 18(2):215-220. PubMed ID: 29265905
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS).
    Ridker PM; Thuren T; Zalewski A; Libby P
    Am Heart J; 2011 Oct; 162(4):597-605. PubMed ID: 21982649
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical trials of antiangiogenic therapy in non-small cell lung cancer: focus on bevacizumab and ZD6474.
    Morgensztern D; Govindan R
    Expert Rev Anticancer Ther; 2006 Apr; 6(4):545-51. PubMed ID: 16613542
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial.
    West H; McCleod M; Hussein M; Morabito A; Rittmeyer A; Conter HJ; Kopp HG; Daniel D; McCune S; Mekhail T; Zer A; Reinmuth N; Sadiq A; Sandler A; Lin W; Ochi Lohmann T; Archer V; Wang L; Kowanetz M; Cappuzzo F
    Lancet Oncol; 2019 Jul; 20(7):924-937. PubMed ID: 31122901
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of pharmaceutically scalable inhaled anti-cancer nanotherapy - Repurposing amodiaquine for non-small cell lung cancer (NSCLC).
    Parvathaneni V; Kulkarni NS; Chauhan G; Shukla SK; Elbatanony R; Patel B; Kunda NK; Muth A; Gupta V
    Mater Sci Eng C Mater Biol Appl; 2020 Oct; 115():111139. PubMed ID: 32600728
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Which is the optimal immunotherapy for advanced squamous non-small-cell lung cancer in combination with chemotherapy: anti-PD-1 or anti-PD-L1?
    Zhang Y; Zhou H; Zhang L
    J Immunother Cancer; 2018 Dec; 6(1):135. PubMed ID: 30509312
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Successes and failures: what did we learn from recent first-line treatment immunotherapy trials in non-small cell lung cancer?
    Remon J; Besse B; Soria JC
    BMC Med; 2017 Mar; 15(1):55. PubMed ID: 28285592
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.